Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
CVS Helath Picks Novo’s Wegovy as Its Weight-Loss Darling, But PBM Firestorm Still Brews In Washington—What’s the Impact, Valuation Outlook & its 5 Key Catalysts?
CVS Health’s Q1 FY25 print delivered a sharp pivot toward earnings normalization, with adjusted EPS of $2.25 and operating income of $4.6B beating expectations, underpinned by double-digit operating profit growth across Health Services and Retail, and a $1.2B YoY lift in Health Care Benefits. The 310bps improvement in medical cost ratio (to 87.3%) and solid $4.6B in FCF affirm near-term strength, while raised FY EPS guidance ($6.00–$6.20) reflects cautious optimism. CVS continues to shed structurally unprofitable verticals, with its ACA exit in 2026 and CostVantage transition bolstering long-term margin health. At the same time, strategic levers are gaining traction: Oak Street’s at-risk member growth (+37% YoY), Signify scaling volumes, and the high-potential Wegovy partnership with Novo Nordisk suggest a defensible pivot into value-based care and metabolic health management. However, pharmacy benefit management (PBM) faces legislative heat, as D.C. intensifies scrutiny on pricing practices, rebates, and pharmacy economics. While Arkansas’ PBM law and upcoming federal proposals pose real risks, CVS’s integrated model, scale, and pharmacy innovation may offer partial insulation. With normalized FCF expected to return to ~$10B and a discounted valuation, we revise to Outperform. Will CVS’s strategic pivot, tech-led execution, and divestment discipline be enough to offset growing policy headwinds and restore margin durability beyond 2025?
